Form 4: SpringWorks Therapeutics Director Disposes of Shares and Options Following Merger with Merck KGaA

A director of SpringWorks Therapeutics, Inc. has reported the disposition of common stock and stock options following the company's acquisition by Merck KGaA for $47.00 per share in cash.

Summary

• Carlos Alban, a director of SpringWorks Therapeutics, Inc. (SWTX), disposed of all his beneficial ownership in the company.
• This disposition occurred on July 1, 2025, as a result of the merger of SpringWorks Therapeutics with EMD Holdings Merger Sub, Inc., a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany.
• Under the merger agreement, each outstanding share of SpringWorks Therapeutics common stock was cancelled and converted into the right to receive $47.00 in cash.
• Carlos Alban disposed of 28,861 shares of common stock, which included 13,480 shares underlying restricted stock units (RSUs).
• He also disposed of stock options to purchase 30,160 shares at an exercise price of $28.93, 13,774 shares at $32.27, and 12,216 shares at $44.77.
• Vested options and RSUs were converted into cash based on the $47.00 merger consideration.
• Unvested options and RSUs were converted into Parent Cash-Based Option Awards and RSU Awards, respectively, which will generally vest according to their original terms, with 50% of each then-unvested tranche vesting on the nine-month anniversary of the merger closing, subject to continued employment.
• Options with an exercise price greater than $47.00 were cancelled for no consideration.

Sentiment

Score: 7

Explanation: The document reports a completed merger, which typically provides a positive liquidity event for shareholders at a pre-determined price. The conversion of unvested equity into cash-based awards with continued vesting terms is also a positive for employees. The only negative is the cancellation of out-of-the-money options for no consideration, which is standard practice in such transactions.

Positives

• The merger provides a clear cash exit for shareholders at $47.00 per share.
• Unvested equity awards (RSUs and options) are converted into cash-based awards, providing continued incentive and value for employees who remain with the acquiring entity.
• The vesting acceleration of 50% of unvested tranches on the nine-month anniversary of closing provides an earlier liquidity event for a portion of the converted awards, subject to continued employment.

Negatives

• Options with an exercise price greater than the $47.00 merger consideration were cancelled for no value.
• Shareholders no longer participate in any potential future upside of SpringWorks Therapeutics as an independent entity.

Future Outlook

The document primarily reports a completed transaction and does not provide forward-looking statements regarding the combined entity's future performance or strategic direction, beyond the vesting terms for converted equity awards.

Industry Context

This transaction represents a strategic acquisition in the biotechnology and pharmaceutical sector, where larger pharmaceutical companies often acquire smaller, innovative biotech firms to expand their pipelines and market presence. Merck KGaA's acquisition of SpringWorks Therapeutics aligns with this trend, aiming to integrate SpringWorks' therapeutic assets into its portfolio.

Comparison to Industry Standards

• The acquisition price of $47.00 per share for SpringWorks Therapeutics common stock would typically be evaluated against recent comparable transactions in the biotech and pharmaceutical M&A landscape, considering factors such as the target company's clinical pipeline, market capitalization, and revenue multiples.
• For instance, recent acquisitions like Pfizer's acquisition of Seagen for $43 billion or AbbVie's acquisition of ImmunoGen for $10.1 billion involved significant premiums over pre-announcement stock prices, reflecting the value placed on oncology and other specialized therapeutic areas.
• Without specific pre-merger stock price data for SWTX, a direct assessment of the premium paid is not possible from this document, but the cash consideration provides immediate liquidity to shareholders.

Stakeholder Impact

• Shareholders: Received $47.00 per share in cash for their common stock, providing immediate liquidity and a defined exit from their investment in SpringWorks Therapeutics.
• Employees (holding unvested equity): Their unvested RSUs and options were converted into cash-based awards, maintaining an incentive structure tied to continued employment with the acquiring entity, Merck KGaA.

Next Steps

• Continued vesting of Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards for eligible employees, with 50% of unvested tranches vesting on the nine-month anniversary of the merger closing, subject to continued employment.

Key Dates

Keywords

SpringWorks Therapeutics, SWTX, Merck KGaA, Merger, Acquisition, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Corporate Action, Biotechnology, Pharmaceuticals